已传文件：photo/1773121782.png
This study investigated a novel in situ immune activation platform for postoperative cancer immunotherapy - the injection-based cold atmospheric plasma (CAP) loaded on the decellularized tumor extracellular matrix (DECM) hydrogel (referred to as CAP-DECM gel). This platform aims to address the recurrence and metastasis problems caused by residual tumor cells in the surgical cavity after surgical resection, while avoiding the limitations of traditional adjuvant therapies such as high systemic toxicity and inconsistent effects. The related research results were published in the top materials science journal "Advanced Materials" under the title "Cold Atmospheric Plasma-Activated Decellularized Extracellular Matrix Gel as a Tumor-Infiltrating Immune Activation Platform for Postoperative Cancer Immunotherapy".
Key innovations
01 Dual-function synergy design
Innovatively integrating the "recruitment" function of decellularized tumor ECM and the "activation" function of cold atmospheric plasma into a single hydrogel platform, it achieved the targeted attraction of residual tumor cells and the effective induction of local immunogenic cell death (ICD).
02 In situ immune activation platform
Transforming the traditionally considered "cavity" of the surgical site into a self-sufficient immune activation "warehouse" that can continuously release immune stimulating signals and reshape the local tumor microenvironment.
03 Potential for combined treatment enhancement
This platform demonstrates a good synergistic effect with existing immune checkpoint blockade therapies (such as anti-PD-L1), providing new ideas for constructing multi-level and personalized postoperative combined immunotherapy schemes.
Journal name: Advanced Materials Publication date: March 13, 2026 DOI: 10.1002/adma.202515444 Research team: Tianxu Fang, Mo Chen, Yueyang Deng, Tianqin Ning, Tianwen Luo, Guojun Chen
